<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">Health</journal-id><journal-title-group><journal-title>Health</journal-title></journal-title-group><issn pub-type="epub">1949-4998</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/health.2012.431171</article-id><article-id pub-id-type="publisher-id">Health-24966</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Non-motor signs and symptoms in Parkinson’s disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>azuo</surname><given-names>Abe</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Clinical Research Center, Osaka Health Science University, Osaka, Japan</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>kazuo.abe@ohsu.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2012</year></pub-date><volume>04</volume><issue>11</issue><fpage>1133</fpage><lpage>1137</lpage><history><date date-type="received"><day>20</day>	<month>August</month>	<year>2012</year></date><date date-type="rev-recd"><day>26</day>	<month>September</month>	<year>2012</year>	</date><date date-type="accepted"><day>8</day>	<month>October</month>	<year>2012</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Motor symptoms are cardinal clinical features of Parkinson’s disease (PD). Progress in drug therapy and rehabilitation has been presenting beneficial effect for motor symptoms. However, non-motor symptoms and signs in PD have been accumulated growing attentions and its amelioration may also give beneficial effect for PD patients’ and their care givers’ quality of life. In this mini-review, I overviewed non-motor symptoms and signs in PD.
 
</p></abstract><kwd-group><kwd>Parkinson’s Disease (PD); Non-Motor Signs and Symptoms; Activities of Daily Livings (ADL); Quality of Life (QOL)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. INTRODUCTION</title><p>James Parkinson described in his historical essay, “Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forwards, and to pass from a walking to a running pace: the senses and intellects being uninjured” [<xref ref-type="bibr" rid="scirp.24966-ref1">1</xref>]. From then, Parkinson’s disease (PD) has been classified as “Movement Disorders” and its clinical diagnosis requires existences of tremor, akinesia, muscle rigidity, and loss of right reflex and has been treated mainly to improve these “motor syndromes” [1-3]. Advent of drug therapy for PD can improve motor function and activities of daily livings (ADL) from their early stages [4-7]. Recently, however, not motor syndrome but non-motor syndrome accumulated attention, because non-motor syndrome such as fatigue, sleep disorders, and dysautonomia closely relate with improvement of their quality of life (QOL) [8-12]. In addition, some researchers consider nonmotor syndrome as an initial signs and symptoms in PD [<xref ref-type="bibr" rid="scirp.24966-ref13">13</xref>].</p><p>In this mini-review, I overviewed non-motor symptoms and signs in PD.</p></sec><sec id="s2"><title>2. NON-MOTOR SIGNS AND SYMPTOMS IN PD</title><p>Numbers of non-motor symptoms and signs in PD constantly increase with accumulation of information of PD clinical pathogenesis. To investigate non-motor symptoms scale for Parkinson’s disease (NMSSPD), we preliminary investigated overall frequency of non-motor symptoms and signs using questioner sheets [11,12]. We investigate neuropsychological signs (depression, apathy, anxiety, anhedonia, cognitive dysfunction, attention deficit, hallucination, delusion, dementia, delirium, panic disorder), sleep disorders (restless leg syndrome, abnormal behavioral disorders in REM period, insomnia, excessive day time sleep, sleep apnea), dysautonomia (orthostatic hypotension, dysuria, impotent), digestion disorders (drooping, incontinence, dysphagia, dysosmia, visual disorder), behavioral disorder (hypersexuality, compulsive behavior, pathological shopping, pathological gambling), and others (fatigue, weight loss, weight gain) [11-16]. Based on results [<xref ref-type="bibr" rid="scirp.24966-ref14">14</xref>], we found that drooping, dysosmia, dysphagia, incontinence, bowel disorder, forgetfulness, inattention, depression, sleep disorder, and abnormal sweating) in PD were significantly increased comparing with those in controls.</p><p>These foregoing investigations indicate that non-motor signs and symptoms in PD have been known to affect their motor syndromes and QOL.</p><sec id="s2_1"><title>2.1. Neuropsychological Syndromes</title><p>PD patients may develop neuropsychiatry syndromes such as hallucination [17,18] or depression [<xref ref-type="bibr" rid="scirp.24966-ref19">19</xref>], which interfere their treatment, care, ADL.</p><p>Unless hallucination affects ADL, full explanation to patients and their caregivers may lighten their burdens. If hallucination in PD needs immediate integrative treatment with psychosocial interventions, antipsychotic medication and adjustment of anti-PD medication are prescribed, however leaving an adequate L-dopa dose to prevent severe off-states [<xref ref-type="bibr" rid="scirp.24966-ref20">20</xref>].</p><p>For people with PD, depression is quite common. Up to 60 percent of people with PD experience mild or moderate depressive symptoms. Research suggests that PD itself causes chemical changes of dopamine, serotonin, and norepinephrine in the limbic system that may lead to depression. Dopamine and dopamine agonist are used for treatment of depression [20-23]. In addition, depression in PD has close relationship with motor dysfunction. Thus, improvement of motor syndrome is the key factor for improvement of depression in PD.</p><p>Anxiety and apathy are dependent syndromes to depression. These signs and symptoms may be found with depression, but may be found without depression unless full drug therapy for motor syndrome conducted [24,25].</p><p>James Parkinson firstly described that PD patients never developed dementia. However, we know that PD patients may develop frontal lobe dysfunction such as forgetfulness [26-28]. PD patients have difficulty planning and carrying through tasks. When facing a task or situation on their own, a person with PD may feel overwhelmed by having to make choices. They may also have difficulty remembering information, or have trouble finding the right words when speaking. To some degree, cognitive impairment affects most PD patients. The same chemical changes that lead to motor symptoms can also result in slowness in thinking [<xref ref-type="bibr" rid="scirp.24966-ref28">28</xref>]. Cognitive impairment in PD is different from dementia, which is a more severe loss of intellectual abilities that interferes with daily living so much that it may not be possible for a person to live independently. Causes cognitive changes in PD remain unclear, but a possible cause is a decreased level of dopamine. However, the cognitive changes associated with dopamine declines are typically mild and circumscribed. It should be noted that PD patients have deep stigma that impairs their cognitive function and increases burden of caregivers.</p></sec><sec id="s2_2"><title>2.2. Sleep Disturbances</title><p>Up to 60% of PD patients have been reported to claim sleep disturbances. PD patients may have difficulty turning over in their sleep due to increased muscle tonus, may be ceased their sleep by pollakisuria, or may have depression [<xref ref-type="bibr" rid="scirp.24966-ref29">29</xref>]. Although non-ergotic dopamine agonists are ropinirole, pramipexole, and rotigotine which have been known to induce day time or sudden insomnia [<xref ref-type="bibr" rid="scirp.24966-ref30">30</xref>], PD itself induces sleep disturbances such as restless leg syndrome (RLS), abnormal behavioral disorders in REM period (RBD), insomnia, excessive day time sleep, and sleep apnea [31-35] PD patients are reported to develop RBD at high frequency up to 40% and have considered these sleep disturbances in their early stage. Thus, diagnosis and treatment of sleep disturbances is a key factor for PD treatment [9,29].</p></sec><sec id="s2_3"><title>2.3. Autonomic Failure (Dysautonomia)</title><p>PD patients frequently show dysautonomia such as orthostatic hypotension [<xref ref-type="bibr" rid="scirp.24966-ref36">36</xref>] and bowel disorders [<xref ref-type="bibr" rid="scirp.24966-ref37">37</xref>]. Unlike patients with multiple systemic atrophy (MSA), PD patients rarely lose their consciousness due to orthostatic hypotension. However, light-headedness or dizziness due to orthostatic hypotension may be a risk factor for accidental falls and injuries after falls [3,8,9]. Since PD patients are tended to have disused syndrome that impairs their ADL and QOL, rehabilitation using tilt table and elastic stockings is needed [15,36]. If their environments require, reform of houses is also planned [38-41].</p><p>PD patients may show pollakisuria, dysuria, feeling of residual urine, or incontinence of urine. Even the same man may develop a wide variety of urinary disorders. PD patients may have sleep disorders due to nocturia [9,33]. These urinary signs are improved after adequate dopamine therapy, but anticholinergic agent such as oxybutynin hydrochloride can improve these [39,41].</p></sec><sec id="s2_4"><title>2.4. Digestive Disorders</title><p>PD patients frequently develop incontinence without antiparkinsonian agents, but antiparkinsonian agents themselves have some effect on developing incontinence. [42,43] Braak et al. pathologically found Lewy bodies in the Auerbach neural plexus that may be result in incontinence in PD [<xref ref-type="bibr" rid="scirp.24966-ref44">44</xref>]. Incontinence has possibility to result in ileus and should be treated with drugs, diet and exercise [<xref ref-type="bibr" rid="scirp.24966-ref45">45</xref>].</p><p>PD patients increasingly show drooping with progression of disease, but patients do not have increased amount of saliva sputum but slowing of swallowing may be a cause [<xref ref-type="bibr" rid="scirp.24966-ref46">46</xref>]. Although some drugs can reduce amount of saliva sputum that increases decayed tooth and periodontal disease, wiping or postural drainage therapy may be useful to prevent aspiration pneumonia.</p><p>To treat dysphagia in PD, nutrition support team (NST) may be useful in daily clinic [47,48].</p></sec><sec id="s2_5"><title>2.5. Sensory Disturbance</title><p>James Parkinson described that PD patients never showed sensory disturbances [<xref ref-type="bibr" rid="scirp.24966-ref1">1</xref>], but many of patients may experience pain or dysesthesia [<xref ref-type="bibr" rid="scirp.24966-ref49">49</xref>] PD patients also demonstrate dysosmia [50,51] and dysgeusia [<xref ref-type="bibr" rid="scirp.24966-ref52">52</xref>] in their early sages. Dopamine is an agent to modulate pain in spinal cord, thalamus, basal ganglia and cingulate gyrus. [53,54] Because of dysregulation of dopamine, PD patients show sensory disturbances. Up to 29% of PD patients complain pain that impedes their QOL [<xref ref-type="bibr" rid="scirp.24966-ref11">11</xref>].</p></sec><sec id="s2_6"><title>2.6. Behavior Disorders</title><p>Disinhibition including hypersexuality, compulsive behavior, pathological shopping, and pathological gambling are also reported as behavior disturbances in PD [11,12]. In our study in Japan, we less frequently observed these behavior disturbances and considered this is because in Japan relatively small amount of antiparkinsonian drugs are used. Amantadine may be effective for disinhibition [<xref ref-type="bibr" rid="scirp.24966-ref54">54</xref>].</p></sec><sec id="s2_7"><title>2.7. Fatigue</title><p>Fatigue is the most trouble but less familiar syndrome in PD [55-60]. Fatigue can be distinguished from depression. Depressions in PD have some relation with motor syndrome, but fatigue does not. Depression also troubles patients’ caregivers [57-60]. Although pathogenesis of fatigue in PD remains uncertain, we hypothesize that it may have some relation with cognitive dysfunction, especially frontal lobe dysfunction (<xref ref-type="fig" rid="fig1">Figure 1</xref>) [56,61].</p></sec><sec id="s2_8"><title>2.8. Others</title><p>PD patients show respiratory dysfunction which results in speech disturbances, dysphagia, and aspiration pneumonia [62,63]. We develop an exercise for PD including respiratory exercise and could improve respiretory dysfunction (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p></sec></sec><sec id="s3"><title>3. CONCLUSION</title><p>Since PD patients are admitted neurological clinic be-</p><p>cause of their motor signs and symptoms such as bradykinesia, tremor, or dystonia, we neurologists mainly pay attention to improve these motor syndrome. However, with advent of PD therapy improve, in some extent, motor syndrome, but nonmotor syndrome has increasingly known to be a crucial factor to improve patients’ and their care givers’ QOL [9,14,57,58]. Pathological examinations mainly by Braak et al. hypothesized that nonmotor syndrome might result from initial pathological changes in PD [<xref ref-type="bibr" rid="scirp.24966-ref44">44</xref>]. Validation of this hypothesis is open for discussion, but for their QOL we should pay more attention for nonmotor syndrome in PD.</p><p><img src="2-8201742.files/image003.gif" /> <img src="2-8201742.files/image004.gif" /></p></sec><sec id="s4"><title>REFERENCES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.24966-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Parkinson, J. (2002) An essay on the shaking palsy. The Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223-236. doi:10.1176/appi.neuropsych.14.2.223</mixed-citation></ref><ref id="scirp.24966-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism, onset, progression and mortality. Neurology, 17, 427-442.  
doi:10.1212/WNL.17.5.427</mixed-citation></ref><ref id="scirp.24966-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jankovic, J. (2008) Parkinson’s disease, clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79, 368-376. doi:10.1136/jnnp.2007.131045</mixed-citation></ref><ref id="scirp.24966-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Duvoisin, R.C. and Sage, J. (2001) Parkinson’s disease. A guide for patient and family. 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia, New York.</mixed-citation></ref><ref id="scirp.24966-ref5"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abe</surname><given-names> K. </given-names></name>,<etal>et al</etal>. (<year>2002</year>)<article-title>Frontier in treatment. Parkinson disease— Role of rehabilitation</article-title><source> Brain Medicine</source><volume> 14</volume>,<fpage> 45</fpage>-<lpage>54</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref6"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Coelho</surname><given-names> M. and Ferreira</given-names></name>,<name name-style="western"><surname> J.J. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2012</year>)<article-title>Late-stage Parkinson disease</article-title><source> Nature Reviews Neurology</source><volume> 8</volume>,<fpage> 435</fpage>-<lpage>442</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Schenkman, M., Hall, D.A., Baron, A.E., Schwartz, R.S., Mettler, P. and Kohrt, W.M. (2012) Exercise for people in early-or midstage Parkinson disease, a 16-month randomized controlled trial. Physical Therapy, 92, 1395-1410.  
doi:10.2522/ptj.20110472</mixed-citation></ref><ref id="scirp.24966-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gr?ber, S., Liepelt-Scarfone, I., Brüssel, T., Schweitzer, K., Gasser, T. and Berg, D. (2011) Self estimated quality of life in monogenetic Parkinson’s disease. Movement Disorders, 26, 187-188. doi:10.1002/mds.23209</mixed-citation></ref><ref id="scirp.24966-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chaudhuri, K.R., Healy, D.G. and Schapira, A.H.V. (2009) Non-motor symptoms of Parkinson’s disease, diagnosis and management. Lancet Neurology, 8, 464-474. 
doi:10.1016/S1474-4422(09)70068-7</mixed-citation></ref><ref id="scirp.24966-ref10"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abe</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> Takanashi</surname><given-names> M. and Yanagihara</given-names></name>,<name name-style="western"><surname> T. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2000</year>)<article-title>Fatigue in patients with Parkin-son’s disease</article-title><source> Behavioural Neurology</source><volume> 12</volume>,<fpage> 103</fpage>-<lpage>106</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Martinez-Martin, P., Schapira, A.H.V. and Stocchi, F. (2007) Prevalence of nonmotor symptoms in Park-inson's disease in an international setting study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders, 22, 1623-1629. doi:10.1002/mds.21586</mixed-citation></ref><ref id="scirp.24966-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chaudhuri, K.R., Martinez-Martin, P., Brown, R.G., Sethi, K., Stocchi, F., Odin, P., Ondo, W., Abe, K., MacPhee, G., MacMahon, D., Barone, P., Rabey, M., Bonnuccelli, U., Forbes, A., Breen, K., Tluk, S., Naidu, Y., Olanow, C.W., Thomas, S., Rye, D., Bowron, A., Williams, A.J. and Schapira, A.H.V. (2007) The metric proper-ties of a novel non-motor symptoms scale for Parkinson’s disease, results from an international pilot study. Movement Disor- ders, 22, 1901-1911. doi:10.1002/mds.21596</mixed-citation></ref><ref id="scirp.24966-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zanigni, S., Calandra-Buonaura, G., Grimaldi, D. and Cortelli, P. (2011) REM behaviour disorder and neurode-generative diseases. Sleep Medicine, 12, S54-S58.  
doi:10.1016/j.sleep.2011.10.012</mixed-citation></ref><ref id="scirp.24966-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Martinez-Martin, P., Rodriguez-Blazquez, C., Abe, K., Bhattacharyya, K.B., Bloem, B.R., Carod-Artal, J., Dill, B., Esselink, R., Falup-Pecurariu, C., Gallardo, M,. Mir, P., Naidu, Y., Nicoletti, A,. Sethi, K., Tsuboi, Y., van Hilten, J.J., Visser, M., Zappia, M. and Chaudhuri, K.R. (2009) International validation of the non-motor symptoms scale, comparison with the pilot study. Neurology, 73, 1584-1591. doi:10.1212/WNL.0b013e3181c0d416</mixed-citation></ref><ref id="scirp.24966-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Martinez-Martin, P., Rodriguez-Blazquez, C., BKurtis, M.M., Chaudhuri, K.R. and The NMSS Validation Group (2011) The impact of non motor symptoms on health-re- lated quality of life of patients with Parkinson’s Disease. Movement Disorders, 26, 399-406.  
doi:10.1002/mds.23462</mixed-citation></ref><ref id="scirp.24966-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism, onset, progression and mortality. Neurology, 17, 427-442.  
doi:10.1212/WNL.17.5.427</mixed-citation></ref><ref id="scirp.24966-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fénelon, G., Mahieux, F. and Huon, R. (2000) Hallucinations in Parkinson’s Disease. Prevelance, phenomenology and risk factors. Brain, 123, 733-745.  
doi:10.1093/brain/123.4.733</mixed-citation></ref><ref id="scirp.24966-ref18"><label>18</label><mixed-citation publication-type="book" xlink:type="simple">Jenner, J. and Laar van, T. (2012) Visual hallucinations in Parkinson’s disease. In: Stone, J.H. and Blouin, M., Eds., International Encyclopedia of Reha-bilitation.  
http://cirrie.buffalo.edu/encyclopedia/en/article/147/</mixed-citation></ref><ref id="scirp.24966-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cummings, J.L. and Masterman, D.L. (1999) Depression in patients with Parkinson’s disease. International Jour- nal of Geriatric Psychiatry, 14, 711-718.  
doi:10.1002/(SICI)1099-1166(199909)14:9&lt;711::AID-GPS4&gt;3.0.CO;2-1</mixed-citation></ref><ref id="scirp.24966-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Remy, P., Doder, M. and Lees, A. (2005) Depression in Parkinson’s disease. Loss of dopamine and nora-drenaline innervations in the limbic system. Brain, 128, 1314-1322. 
doi:10.1093/brain/awh445 </mixed-citation></ref><ref id="scirp.24966-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Rektorova, I., Rektor, I. and Bares, M. (2003) Pramipex- ole and pergolide in the treatment of depression in Parkinson’s disease, a national multicentre prospective randomized study. European Journal of Neurology, 10, 399- 406. doi:10.1046/j.1468-1331.2003.00612.x</mixed-citation></ref><ref id="scirp.24966-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Barone, P., Scarzella, L. and Marconi, R. (2006) Pramipex- ole versus ser-traline in the treatment of depression in Parkinson’s disease. A national multicenter parallel group randomized study. Journal of Neurology, 253, 601-607.  
doi:10.1007/s00415-006-0067-5</mixed-citation></ref><ref id="scirp.24966-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Lemke, M.R., Brecht, H.M. and Koester, J. (2005) Anhedonia, depression and motor functioning in Parkinson’s disease during treatment with pramipexole. The Journal of Neuropsychiatry and Clinical Neurosciences, 17, 214- 220. doi:10.1176/appi.neuropsych.17.2.214</mixed-citation></ref><ref id="scirp.24966-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Czernecki, V., Pillon, B. and Houeto, J.L. (2002) Motiva- tion, reward and Parkinson’s disease, influence of dopa therapy. Neuropsychologia, 40, 2257-2267. 
doi:10.1016/S0028-3932(02)00108-2</mixed-citation></ref><ref id="scirp.24966-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Aarsland, D., An-dersen, K., Larsen, J.P., Lolk, A. and Kragh-S?rensen, P. (2003) Prevalence and characteristics of dementia in Parkinson disease. Archives of Neurology, 60, 387-392. doi:10.1001/archneur.60.3.387</mixed-citation></ref><ref id="scirp.24966-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Williams-Gray, C.H., Foltynie, T. and Brayne, C.E.G. (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain, 130, 1787-1798.  
doi:10.1093/brain/awm111</mixed-citation></ref><ref id="scirp.24966-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Cooper, J.A., Sagar, H.J. and Jordan, N. (1991) Cognitive impairment in early, untreated Parkinson’s disease and its relationship to motor disability. Brain, 114, 2095-2122. 
doi:10.1093/brain/114.5.2095</mixed-citation></ref><ref id="scirp.24966-ref28"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fujiwara</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Yamauchi</surname><given-names> K. and Abe</given-names></name>,<name name-style="western"><surname> K. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>Rehabilitation in Parkinson disease</article-title><source> Monthly Book Medical Rehabilitation</source><volume> 76</volume>,<fpage> 44</fpage>-<lpage>52</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Chaudhuri, K.R., Pal, S. and DiMarco, A. (2002) The Parkinson’s disease sleep scale, a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. Journal of Neurology, Neurosurgery &amp; Psychiatry, 73, 629-635. doi:10.1136/jnnp.73.6.629</mixed-citation></ref><ref id="scirp.24966-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Homann, C.N., Wenzel, K., Suppan, K., Ivanic, G., Kriech- baum, N., Crevenna, R. and Ott, E. (2002) Sleep attacks in patients taking dopamine agonists, review. BMJ, 324, 1483-1487. doi:10.1136/bmj.324.7352.1483</mixed-citation></ref><ref id="scirp.24966-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Diagnostic Classification Steering Committee (1990) International classification of sleep disorders, diagnostic and coding manual. American Sleep Disorders Association, Rochester.</mixed-citation></ref><ref id="scirp.24966-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Abe, K., Hikita, T. and Sakoda, S. (2005) Sleep disturbances in Japanese patients with Parkinson’s disease-Comparing with patients in the UK. Journal of Neurol Science, 234, 73-78. doi:10.1016/j.jns.2005.03.036</mixed-citation></ref><ref id="scirp.24966-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Abe, K., Hikita, T. and Sakoda, S. (2005) Zolpidem tartrate therapy for sleep disturb-ances in patients with Parkinson’s disease. Journal of the Neurological Sciences, 238, S350. doi:10.1016/S0022-510X(05)81350-4</mixed-citation></ref><ref id="scirp.24966-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Goetz, C.G., Ouyang, B., Negron, A. and Stebbins, G.T. (2010) Hallucinations and sleep disorders in PD, ten-year prospective longitudinal study. Neurology, 75, 1773-1779. 
doi:10.1212/WNL.0b013e3181fd6158</mixed-citation></ref><ref id="scirp.24966-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Abe, K. (2008) Zolpidem therapy for movement disorders. Recent Patents on CNS Drug Discovery, 3, 55-60.  
doi:10.2174/157488908783421519</mixed-citation></ref><ref id="scirp.24966-ref36"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Medow</surname><given-names> M.S.</given-names></name>,<name name-style="western"><surname> Stewart</surname><given-names> J.M.</given-names></name>,<name name-style="western"><surname> Sanyal</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> Mumtaz</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> Sica</surname><given-names> D. and Frishman</given-names></name>,<name name-style="western"><surname> W.H. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasova- gal syncope</article-title><source> Cardiology in Review</source><volume> 16</volume>,<fpage> 4</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Fitzmaurice, H., Fowler, C.J, Rickards, D., Kirby, R.S., Quinn, N.P., Marsden, C.D., Milroy, E.J. and Turner- Warwick, R.T. (1985) Micturition disturbance in Parkinson’s disease. British Journal of Urology, 57, 652-656. 
doi:10.1111/j.1464-410X.1985.tb07025.x</mixed-citation></ref><ref id="scirp.24966-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Duncan, R.P., Leddy, A.L., Cavanaugh, J.T., Dibble, L.E., Ellis, T.D., Ford, M.P., Foreman, K.B. and Earhart, G.M. (2012) Accuracy of fall prediction in Parkinson disease, six-month and 12-month pro-spective analyses. Parkinson’s Disease, 237673.</mixed-citation></ref><ref id="scirp.24966-ref39"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clarke</surname><given-names> C.E.</given-names></name>,<name name-style="western"><surname> Zobkiw</surname><given-names> R.M. and Gullaksen</given-names></name>,<name name-style="western"><surname> E. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1995</year>)<article-title>Quality of life and care in Parkinson’s disease</article-title><source> British Journal of Clinical Practice</source><volume> 49</volume>,<fpage> 288</fpage>-<lpage>293</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref40"><label>40</label><mixed-citation publication-type="book" xlink:type="simple">Kamata, N. and Abe, K. (2008) Accidental falls and overestimation of stability limits in Parkinsonian patients. In: Murray, C.A., Ed., Accidental Falls, Causes, Prevention, and Interventions, Nova Science Publishers and Inc., New York, 200-243.</mixed-citation></ref><ref id="scirp.24966-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Jain, S. and Goldstein, D.S. (2012) Cardiovascular dysautonomia in Parkinson disease, from pathophysiology to pathogenesis. Neurobiology of Disease, 46, 572-580.  
doi:10.1016/j.nbd.2011.10.025</mixed-citation></ref><ref id="scirp.24966-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Singharam, C., Ashraf, W. and Gaummitz, E.A. (1995) Dopaminergic defect of enteric nervous system in Park- inson’s disease patients with chronic constipation. Lancet, 346, 861-864. doi:10.1016/S0140-6736(95)92707-7</mixed-citation></ref><ref id="scirp.24966-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Abbott, R.D., Petrovitch, H. and White, L.R. (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology, 57, 456-462.  
doi:10.1212/WNL.57.3.456</mixed-citation></ref><ref id="scirp.24966-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen-Steur, E.N. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24, 197-211.  
doi:10.1016/S0197-4580(02)00065-9</mixed-citation></ref><ref id="scirp.24966-ref45"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clark</surname><given-names> E.C.</given-names></name>,<name name-style="western"><surname> Mulder</surname><given-names> D.W.</given-names></name>,<name name-style="western"><surname> Erickson</surname><given-names> D.J.</given-names></name>,<name name-style="western"><surname> Clements</surname><given-names> B.G. and Maccaty</given-names></name>,<name name-style="western"><surname> C.S. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1957</year>)<article-title>Parkinson’s disease, therapeutic exercises in its management</article-title><source> Postgraduate Medicine</source><volume> 21</volume>,<fpage> 301</fpage>-<lpage>308</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Kalf, J.G., de Swart, B.J., Borm, G.F., Bloem, B.R. and Munneke, M. (2009) Prevalence and definition of drooling in Parkinson’s disease, a systematic review. Journal of Neurology, 256, 1391-1396.  
doi:10.1007/s00415-009-5098-2</mixed-citation></ref><ref id="scirp.24966-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Salat-Foix, D. and Suchowersky, O. (2012) The management of gastrointestinal symptoms in Parkinson’s disease. Expert Review of Neurotherapeutics, 12, 239-248. 
doi:10.1586/ern.11.192</mixed-citation></ref><ref id="scirp.24966-ref48"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lyons</surname><given-names> K.E. and Pahwa</given-names></name>,<name name-style="western"><surname> R. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2011</year>)<article-title>The impact and management of nonmotor symptoms of Parkinson’s disease</article-title><source> American Journal of Managed Care</source><volume> 17</volume>,<fpage> S308</fpage>-<lpage>S314</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Quinn, N.P., Koller, W.C., Lang, A.E. and Marsden, C.D. (1986) Painful Parkinson’s disease. Lancet II, 1366-1369. 
doi:10.1016/S0140-6736(86)91674-0</mixed-citation></ref><ref id="scirp.24966-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Shah, M., Deeb, J., Fernando, M., Noyce, A., Visentin, E., Findley, L.J. and Hawkes, C.H. (2009) Abnormality of taste and smell in Parkinson’s disease. Parkinsonism and Related Disorders, 15, 232-237.  
doi:10.1016/j.parkreldis.2008.05.008</mixed-citation></ref><ref id="scirp.24966-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Landis, B.N. and Burkhard, P.R. (2008) Rhinorrhea and olfaction in Parkinson disease. Neurology, 71, 1041-1042. 
doi:10.1212/01.wnl.0000327867.15757.d0</mixed-citation></ref><ref id="scirp.24966-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Chudler, E.H. and Dong, W.K. (1950) The role of the basal ganglia in nociception and pain. Pain, 60, 3-38.  
doi:10.1016/0304-3959(94)00172-B</mixed-citation></ref><ref id="scirp.24966-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Shyu, B.C., Kititsy-Roy, J.A. and Morrow, T.J. (1992) Neurophysiological, pharmacological and behavioural evidence for medial thalamic mediation of cocaine induced dopaminergic analgesia. Brain Research, 522, 216-223. 
doi:10.1016/0006-8993(92)90472-L</mixed-citation></ref><ref id="scirp.24966-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Weintraub, D., Sohr, M., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G.R. and Lang, A.E. (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology, 68, 963-968. 
doi:10.1002/ana.22164</mixed-citation></ref><ref id="scirp.24966-ref55"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abe</surname><given-names> K. </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>Tiredness and fatigue</article-title><source> Journal of International Society of Life Information Science</source><volume> 24</volume>,<fpage> 60</fpage>-<lpage>62</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref56"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abe</surname><given-names> K. </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Tiredness and fatigue</article-title><source> Brain</source><volume> 21</volume>,<fpage> 35</fpage>-<lpage>39</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref57"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abe</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> Takanashi</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Yanagihara</surname><given-names> T. and Sakoda</given-names></name>,<name name-style="western"><surname> S. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2002</year>)<article-title>Pergolide mesilate may improve fatigue in patients with Parkinson’s disease</article-title><source> Behavioural Neurology</source><volume> 13</volume>,<fpage> 117</fpage>-<lpage> 121</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.24966-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Schrag, A., Jahanshahi, M. and Quinn, N. (2000) What contributes to quality of life in patients with Parkinson’s disease? Journal of Neurology Neurosurgery &amp; Psychiatry, 69, 308-312. doi:10.1136/jnnp.69.3.308</mixed-citation></ref><ref id="scirp.24966-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Martinez-Martine, P., Benito-León, J., Alonso, F., Catalán, M.J., Pondal, M., Zamarbide, I., Tobías, A., de Pedro, J. Quality of life of caregivers in Parkinson’s disease. Quality of Life Research, 14, 463-472. 
doi:10.1007/s11136-004-6253-y</mixed-citation></ref><ref id="scirp.24966-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Krupp, L.B., Coyle, P.K. and Doscher, C. (1995) Fatigue therapy in multiple svlerosis—Results of a double-blind, randomized, parallel trial of amantadine, remoline, and placebo. Neurology, 45, 1956-1961.  
doi:10.1212/WNL.45.11.1956</mixed-citation></ref><ref id="scirp.24966-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Pavese, N., Metta, V,. Bose, S.K., Chaudhuri, K.R. and Brooks, D.J. (2010) Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain, 33, 3434-3443. doi:10.1093/brain/awq268</mixed-citation></ref><ref id="scirp.24966-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Tamaki, A., Matsuo, Y. and Abe, K. (2000) Influence of Thoracoabdominal movement on pulmonary function in patients with Parkinson’s disease. Comparison with healthy subjects. Neurorehabilitation and Neural Repair, 14, 43- 47. doi:10.1177/154596830001400105</mixed-citation></ref><ref id="scirp.24966-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Matsuo, Y., Kamata, N. and Abe, K. (2006) Thoraco-abnominal movements during deep breathing in patients with Parkinson’s disease may be reduced parallel to disease progression. Clinical Neurophysiology, 117, S185. 
doi:10.1016/j.clinph.2006.06.334</mixed-citation></ref></ref-list></back></article>